{"id":"mk0869-aprepitant","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hiccups"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprepitant crosses the blood-brain barrier and competitively binds to NK1 receptors, preventing substance P from activating these receptors. Substance P is a key neurotransmitter involved in the emetic (vomiting) pathway, particularly in response to chemotherapy. By blocking NK1 receptors, aprepitant suppresses both acute and delayed chemotherapy-induced nausea and vomiting (CINV).","oneSentence":"Aprepitant is a selective antagonist of neurokinin-1 (NK1) receptors that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center of the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:51.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"},{"name":"Post-operative nausea and vomiting (PONV) prevention"}]},"trialDetails":[{"nctId":"NCT07081256","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":665},{"nctId":"NCT06931119","phase":"PHASE1","title":"Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Rabin Medical Center","startDate":"2025-05-30","conditions":"Pruritus","enrollment":30},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT05773950","phase":"NA","title":"Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention","status":"ENROLLING_BY_INVITATION","sponsor":"Samsung Medical Center","startDate":"2023-08-18","conditions":"Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy","enrollment":144},{"nctId":"NCT04054193","phase":"PHASE4","title":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":103},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT01186029","phase":"NA","title":"Comparison of Adding EMEND to PONV/PDNV Treatment Regimen","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2011-09-01","conditions":"Postoperative Nausea and Vomiting","enrollment":""},{"nctId":"NCT06427681","phase":"EARLY_PHASE1","title":"An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Zhuhai Beihai Biotech Co., Ltd","startDate":"2024-05","conditions":"Bioavailability","enrollment":40},{"nctId":"NCT01851369","phase":"PHASE1, PHASE2","title":"TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-12","conditions":"Lymphomas, Solid Tumors, NSCLC","enrollment":93},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT01020903","phase":"NA","title":"Aprepitant for Post-operative Nausea","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2009-11","conditions":"Postoperative Nausea","enrollment":200},{"nctId":"NCT05509634","phase":"PHASE3","title":"Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2022-09-21","conditions":"Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy","enrollment":754},{"nctId":"NCT05755659","phase":"NA","title":"Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV.","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-07-15","conditions":"Neoplasms","enrollment":3000},{"nctId":"NCT05632224","phase":"PHASE4","title":"Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery","status":"UNKNOWN","sponsor":"Baskent University","startDate":"2022-11-24","conditions":"Postoperative Nausea, Vomiting","enrollment":60},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT01334086","phase":"PHASE2","title":"Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-09","conditions":"Acute Myeloid Leukemia","enrollment":41},{"nctId":"NCT01527994","phase":"PHASE1","title":"Aprepitant Effects in Intravenous Heroin Dependence","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-01","conditions":"Opioid Dependence","enrollment":64},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT00711555","phase":"PHASE2","title":"Emend for Multiple-day Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2005-11","conditions":"Nausea, Vomiting","enrollment":22},{"nctId":"NCT01504711","phase":"NA","title":"Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy","status":"COMPLETED","sponsor":"Philip Philip","startDate":"2012-06","conditions":"Gastrointestinal Cancer, Nausea Post Chemotherapy","enrollment":30},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT00819039","phase":"PHASE1","title":"A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01-26","conditions":"Postoperative Nausea and Vomiting","enrollment":98},{"nctId":"NCT00588835","phase":"PHASE4","title":"Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2008-03","conditions":"Tumor","enrollment":20},{"nctId":"NCT02364804","phase":"","title":"A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shiga University","startDate":"2012-04","conditions":"Non-small Cell Lung Cancer","enrollment":10},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT01176591","phase":"PHASE2","title":"HBPL Study of the Impact of the NK1 Antagonist Aprepitant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-09","conditions":"Cocaine Dependence, Alcohol Dependence","enrollment":13},{"nctId":"NCT02161991","phase":"PHASE3","title":"Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-02-01","conditions":"Carcinoma, Non-small Cell Lung","enrollment":244},{"nctId":"NCT03889366","phase":"PHASE1","title":"Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers","status":"COMPLETED","sponsor":"Nuformix Technologies Limited","startDate":"2019-03-20","conditions":"Healthy","enrollment":12},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01149369","phase":"PHASE2","title":"Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-04","conditions":"Gastroparesis","enrollment":126},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT02989467","phase":"PHASE1","title":"Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-01-27","conditions":"Healthy","enrollment":27},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01732458","phase":"PHASE2","title":"A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-02-12","conditions":"Post-operative Nausea, Post-operative Vomiting","enrollment":229},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT01405924","phase":"PHASE2","title":"Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-25","conditions":"Nausea, Vomiting","enrollment":111},{"nctId":"NCT01534637","phase":"PHASE2","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2006-08","conditions":"Extrahepatic Bile Duct Cancer, Nausea, Vomiting","enrollment":22},{"nctId":"NCT00781768","phase":"PHASE4","title":"Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea","status":"COMPLETED","sponsor":"Loyola University","startDate":"2003-08","conditions":"Nausea, Vomiting","enrollment":181},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT01450826","phase":"PHASE2","title":"Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide","status":"COMPLETED","sponsor":"Katy Peters","startDate":"2014-06-24","conditions":"Nausea, Vomiting, Glioma","enrollment":136},{"nctId":"NCT01874119","phase":"PHASE2","title":"Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma","status":"TERMINATED","sponsor":"St. Louis University","startDate":"2013-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":13},{"nctId":"NCT01275664","phase":"NA","title":"Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"2011-06","conditions":"Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma","enrollment":4},{"nctId":"NCT02532634","phase":"PHASE4","title":"Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2015-08-19","conditions":"Cancer, Tumors","enrollment":292},{"nctId":"NCT00970905","phase":"PHASE2","title":"Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2009-10","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT01649258","phase":"PHASE1","title":"Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2012-09-04","conditions":"Breast Cancer, Nausea, Vomiting","enrollment":29},{"nctId":"NCT00871910","phase":"PHASE1","title":"Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-11","conditions":"Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":81},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT02210195","phase":"PHASE2","title":"Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2014-09-04","conditions":"Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder","enrollment":20},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00952341","phase":"PHASE3","title":"Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-08-25","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":421},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00895245","phase":"PHASE2","title":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx","enrollment":6},{"nctId":"NCT01625455","phase":"PHASE4","title":"Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2012-02","conditions":"Sezary Syndrome, Pruritus","enrollment":7},{"nctId":"NCT01031953","phase":"PHASE1, PHASE2","title":"Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2008-08","conditions":"Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":34},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT00090246","phase":"PHASE3","title":"2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-05-13","conditions":"Postoperative Nausea and Vomiting","enrollment":922},{"nctId":"NCT00034944","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-24","conditions":"Major Depressive Disorder","enrollment":495},{"nctId":"NCT00048607","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-07-30","conditions":"Major Depressive Disorder","enrollment":600},{"nctId":"NCT00092196","phase":"PHASE3","title":"Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-12-01","conditions":"Nausea, Vomiting, Breast Neoplasms","enrollment":820},{"nctId":"NCT00035048","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-21","conditions":"Major Depressive Disorder","enrollment":540},{"nctId":"NCT00090155","phase":"PHASE3","title":"2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-09-26","conditions":"Postoperative Nausea and Vomiting","enrollment":805},{"nctId":"NCT00042029","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-06-18","conditions":"Major Depressive Disorder","enrollment":324},{"nctId":"NCT00092183","phase":"PHASE4","title":"An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-10-10","conditions":"Nausea, Vomiting, Breast Neoplasms","enrollment":866},{"nctId":"NCT00048594","phase":"PHASE3","title":"Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-01-03","conditions":"Major Depressive Disorder","enrollment":800},{"nctId":"NCT01611948","phase":"PHASE2","title":"Treatment for Cannabis Withdrawal and Dependence","status":"COMPLETED","sponsor":"The Scripps Research Institute","startDate":"2011-05","conditions":"Cannabis Dependence","enrollment":70},{"nctId":"NCT00034983","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-10-29","conditions":"Major Depressive Disorder","enrollment":900},{"nctId":"NCT00090207","phase":"PHASE4","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-01-13","conditions":"Nausea, Vomiting","enrollment":477},{"nctId":"NCT01249001","phase":"PHASE2","title":"Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2010-10","conditions":"Nausea, Vomiting, Chemotherapy","enrollment":4},{"nctId":"NCT00035009","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09-20","conditions":"Major Depressive Disorder","enrollment":468},{"nctId":"NCT00035295","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-11-08","conditions":"Major Depressive Disorder","enrollment":584},{"nctId":"NCT02097823","phase":"PHASE2","title":"Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy","status":"COMPLETED","sponsor":"Indiana University","startDate":"2014-02","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT00428519","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01432015","phase":"PHASE4","title":"Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Gynecologic Oncology Associates","startDate":"2011-09","conditions":"Ovarian Cancer, Uterine Cancer","enrollment":20},{"nctId":"NCT02550119","phase":"NA","title":"Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-04-19","conditions":"Malignant Digestive System Neoplasm, Nausea and Vomiting","enrollment":19},{"nctId":"NCT00619359","phase":"PHASE3","title":"Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":2322},{"nctId":"NCT00600353","phase":"PHASE2","title":"Multi-day Doses in Prevention of Nausea and Emesis","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2007-10","conditions":"Myeloma, Plasma-Cell, Lymphoma, Malignant","enrollment":20},{"nctId":"NCT01913990","phase":"PHASE4","title":"Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2011-09","conditions":"Emesis","enrollment":323},{"nctId":"NCT02576327","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Jun Zhu","startDate":"2015-10","conditions":"Vomiting","enrollment":130},{"nctId":"NCT01300988","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-12","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT01490060","phase":"NA","title":"Fosaprepitant in Patients Receiving Ifosfamide-based Regimen","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-05","conditions":"Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy","enrollment":47},{"nctId":"NCT02525848","phase":"PHASE2, PHASE3","title":"Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries","status":"COMPLETED","sponsor":"Assiut University","startDate":"2015-08","conditions":"Postoperative Nausea and Vomiting","enrollment":150},{"nctId":"NCT00293384","phase":"NA","title":"Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2004-10","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":40},{"nctId":"NCT02445872","phase":"PHASE2","title":"Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-12","conditions":"Chemotherapy-Induced Nausea and Vomiting, Lung Cancer","enrollment":80},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT00896038","phase":"PHASE2","title":"The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2009-05","conditions":"Alcoholism, Alcohol Dependence, Posttraumatic Stress Disorder","enrollment":58},{"nctId":"NCT02357693","phase":"PHASE4","title":"Neurokinin Receptor Antagonist Associated to Ondansetron in PONV","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2015-02","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT00990821","phase":"PHASE1","title":"A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01","conditions":"Chemotherapy-Induced Nausea and Vomiting, Postoperative Nausea and Vomiting","enrollment":188},{"nctId":"NCT00231777","phase":"PHASE3","title":"A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Post-Operative Nausea and Vomiting","enrollment":216},{"nctId":"NCT00954941","phase":"PHASE2","title":"Ondansetron Versus Aprepitant Plus Ondansetron for Emesis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-11","conditions":"Hematologic Diseases, Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":100},{"nctId":"NCT02226601","phase":"NA","title":"Aprepitant to Mitigate Opioids' Cognitive Side Effects","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2014-10","conditions":"Cognitive Dysfunction","enrollment":50},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01074697","phase":"PHASE3","title":"Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2010-04","conditions":"Nausea, Vomiting, Genital Neoplasms, Female","enrollment":246},{"nctId":"NCT01074255","phase":"","title":"Re-examination Study of EMEND (Aprepitant) (MK-0869-184)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":3546},{"nctId":"NCT02407600","phase":"PHASE2","title":"Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy","status":"UNKNOWN","sponsor":"Ajeet Gajra","startDate":"2015-04","conditions":"Non-small Cell Lung Cancer, Vomiting, Nausea","enrollment":150},{"nctId":"NCT01017809","phase":"NA","title":"Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2010-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT01111851","phase":"PHASE1","title":"Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":16},{"nctId":"NCT00035282","phase":"PHASE3","title":"Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-09","conditions":"Major Depressive Disorder","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1343,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MK0869, aprepitant","genericName":"MK0869, aprepitant","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant is a selective antagonist of neurokinin-1 (NK1) receptors that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center of the brain. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy, Post-operative nausea and vomiting (PONV) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}